(MYMD) – StreetInsider.com Reports
-
MyMD Pharmaceuticals (MYMD) Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
-
MyMD Pharmaceuticals (MYMD) Announces 1:30 Reverse Share Split
-
MyMD Pharmaceuticals (MYMD) Reports Positive Results for Sarcopenia Drug
-
MyMD Pharmaceuticals (MYMD) Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis
-
MyMD Pharmaceuticals (MYMD) Announces Preclinical Study Results Supera-CBD Reduced Acute Inflammatory Pain
-
MyMD Pharmaceuticals (MYMD) Announces FDA Accepts IND for Phase 2 Study of oral TNF-α inhibitor MYMD-1 in Rheumatoid Arthritis
-
MyMD Pharmaceuticals (MYMD) to Resume Trading at 9:50 a.m.
-
MyMD Pharmaceuticals (MYMD) Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1 in Sarcopenia/Age-Related Frailty
-
MyMD Pharmaceuticals (MYMD) Halted, News Pending
-
MyMD Pharmaceuticals (MYMD) and Charles River Present Positive Data for MYMD-1
-
MyMD Pharmaceuticals (MYMD) Announces U.S. DEA Determines Supera-CBD is not a Controlled Substance or Listed Chemical
-
MyMD Pharmaceuticals (MYMD) Announces $15 Million Offering with Existing Investors
-
MyMD Pharmaceuticals (MYMD) Announces Publication of Phase 1 Data for MYMD-1
-
MyMD Pharmaceuticals (MYMD) Provides Dosing Update on Phase 2 Trial of MYMD-1
-
MyMD Pharmaceuticals (MYMD) Receives Grant From European Patent Office for Supera-CBD Compound
-
MyMD Pharmaceuticals (MYMD) been granted European patent - Patent Grants
-
MyMD Pharmaceuticals (MYMD) Announces Data Showing MYMD-1 May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences
-
MyMD Pharmaceuticals (MYMD) Advances Phase 2 Multi-Center Clinical Trial of MYMD-1
-
MyMD Pharmaceuticals (MYMD) Collaborates with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions
-
MyMD Pharmaceuticals (MYMD) Announces Further Advances of Phase 2 Trial of MYMD-1
-
MyMD Pharmaceuticals (MYMD) received a decision to grant European patent number EP3755318 - Patent Grants
-
MyMD Pharmaceuticals' (MYMD) Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical Model of Rheumatoid Arthritis
-
MyMD Pharmaceuticals (MYMD) Accelerates Patient Dosing in Phase 2 Clinical Trial of MYMD-1
-
MyMD Pharmaceuticals (MYMD) Reports Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1
-
MyMD Pharmaceuticals (MYMD) Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia
-
MyMD Pharmaceuticals' (MYMD) Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia
-
MyMD Pharmaceuticals (MYMD) Director Buys 15K Shares
-
MyMD Pharmaceuticals (MYMD) Announces Issuance of U.S. Patent Covering Lead Drug Candidate MYMD-1 in a Method of Extending Lifespan
-
MyMD Pharmaceuticals (MYMD) Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Lati
-
MyMD Pharmaceuticals (MYMD) Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan
-
MyMD Pharmaceuticals (MYMD) Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD
-
MyMD Pharmaceuticals (MYMD) Announces Issuance of U.S. Patent for Use of Lead Candidate MYMD-1 for Treating Fibrosis and Asthma
-
MyMD Pharmaceuticals (MYMD) Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases
-
MyMD Pharmaceuticals (MYMD) Halted on LUDP
-
MyMD Pharmaceuticals (MYMD) Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine
-
MyMD Pharmaceuticals (MYMD) Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study
-
MyMD Pharmaceuticals (MYMD) Lead Compound MYMD-1 Shows Commonality in Comparative Study with FDA-Approved Anti-Inflammatory and Anti-Autoimmune Drugs Used for Arthritis, Colitis and Dermatitis
-
MyMD Pharmaceuticals (MYMD) Announces New Data from Comparative Study on Lead Compound MYMD-1
-
Johns Hopkins Medicine Researchers to Present Data on MyMD Pharmaceuticals' (MYMD) Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit
-
MyMD Pharmaceuticals (MYMD) Announces Issuance of Allowance from United States Patent and Trademark Office for Synthetic Cannabinoid Compounds
Back to MYMD Stock Lookup
